Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5681525 | Medicine - Programa de Formación Médica Continuada Acreditado | 2016 | 11 Pages |
Abstract
Except in CML, where tyrosine kinase inhibitors (TKI) are the standard treatment, in the remaining MPD the treatment is based on cyto-reduction and control of symptoms. In some of these entities, as in primary myelofibrosis, JAK inhibitors are being used. In any case allogeneic hematopoietic stem cell transplantation remains the only curative treatment, although only a small portion of these patients can benefit from this procedure.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
O.J. Ferré, F. Sánchez-Guijo,